About the Company
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stagepreclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.
Employees
10
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MNPR News
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative ...
Monopar Therapeutics Inc
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development ...
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer ...
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing innovative treatments for cancer patients. Monopar's pipeline ...
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer ...
What's Going On With Cancer-Focused Monopar Therapeutics Stock Today?
Monopar Therapeutics Inc (NASDAQ:MNPR) shares jumped during the trading session on Thursday on a strong volume session volume of 16.179 million, compared to an average volume of 1.817 million ...
Monopar Therapeutics Inc MNPR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, ...
Monopar Therapeutics Inc (MNPR)
Monopar Therapeutics Inc . (Nasdaq: NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced... Monopar Therapeutics ...
Loading the latest forecasts...